Instil Bio (TIL)

• Market cap: $48.4M
• 1 day: 0.85%
• 5 days: -2.19%
• 1 month: -8.71%
• 3 months: -5.69%
• 6 months: -15.32%
• Year to date: -36.73%
• 1 year: -63.19%
• 5 years: -98.34%
• 10 years: -98.65%
• Sector: Healthcare
• Industry: Biotechnology

About: Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Employees: 17